You are about to leave
this Takeda website
Takeda has no control over the content or presentation of the third-party site you are about to view.
Sharon, diagnosed with moderate B.E.D. and treated with Vyvanse
Learn more about Vyvanse and take a look at its results in clinical studies.
In two 12-week studies of adults who were diagnosed with moderate to severe B.E.D., Vyvanse was proven to reduce the number of weekly binge days (a day with at least 1 binge episode).
At the end of both Study 1 and Study 2, adults with moderate to severe B.E.D. who took Vyvanse experienced, on average, significantly fewer binge days per week compared to those who took placebo. The change in binge days per week for adult patients with moderate to severe B.E.D. from the start of the study to the end was measured using a statistical measure called the LS-Mean.*
*LS-Mean is a statistical method used in the clinical studies to calculate an average score.
†On average from the start of the 12-week study to its end.
Do not take Vyvanse if you are taking or have taken within the past 14 days an antidepressant called a monoamine oxidase inhibitor (MAOI) or are sensitive to, allergic to, or had a reaction to other stimulant medications.
Concerned about side effects? Talk to your doctor.
The same 2 studies also looked at obsessive binge eating thoughts and compulsive binge eating behaviors. A tool used by doctors called the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) measured Vyvanse compared to sugar pill.
Patients treated with Vyvanse had average improvement in the
Y-BOCS-BE total score of 72% and 73%, and patients treated
with sugar pill had improvement of 31% and 34% at the final
visit of each of the 12-week studies.
‡At the final visit of each of the 12-week studies
In the 2 studies, doctors rated patients as much improved or very much improved ("improved") or "not
improved," using the Clinical Global Impressions—Improvement rating scale (CGI-I).
In the 2 studies, the percentage of patients who had no binge eating episodes in the last 4 weeks was measured. This was defined as a patient who experienced no binge eating episodes during the 4 weeks leading up to the patient's last visit of the study. Patients taking Vyvanse were more likely to have no binge eating episodes during this 4-week time period compared to patients taking sugar pill.
Vyvanse effectively controlled symptoms in a 38-week study. In this study, patients who initially responded to Vyvanse had a longer time to relapse compared to those who were switched to sugar pill. Relapse was defined as a worsening in both the number of binge eating days (2 or more per week for 2 consecutive weeks) and the symptom severity score determined by the healthcare provider. For patients who continued on Vyvanse, 4% had relapse vs 36% of patients on placebo. Adverse events seen in this study were consistent with those seen in other studies of adult patients with moderate to severe B.E.D. on Vyvanse.
Among patients who continued on Vyvanse, 96% continued to have symptom control. Among patients who were switched to placebo, 68% continued to have symptom control.
Serious heart-related problems can occur while taking stimulants, like Vyvanse, including:
Tell your doctor about any heart problems, heart defects, and/or high blood pressure, or if you have a family history of these problems. Your doctor should check your blood pressure and heart rate regularly during treatment.
Call your doctor right away if you have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Vyvanse.
Information that can help you prepare for your conversation.
Learn about Vyvanse dosing.